- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Bioventus Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 01.06. | Transcript: Bioventus Q1 2026 Earnings Conference Call | 1 | Benzinga.com | ||
| 29.05. | Bioventus (BVS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now | 1 | Zacks | ||
| 21.05. | Bioventus Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.05. | Bioventus outlines 2026 adjusted EPS of $0.75-$0.79 while reaffirming $600M-$610M revenue | 1 | Seeking Alpha | ||
| 06.05. | Bioventus nach starkem Quartal: Gewinnprognose für 2026 angehoben | 1 | Investing.com Deutsch | ||
| BIOVENTUS Aktie jetzt für 0€ handeln | |||||
| 06.05. | Bioventus Q1 2026 slides: earnings beat drives guidance raise | 1 | Investing.com | ||
| 06.05. | Bioventus Non-GAAP EPS of $0.15 beats by $0.08, revenue of $132.1M beats by $2.2M | 2 | Seeking Alpha | ||
| 06.05. | Bioventus, Inc.: Bioventus Reports First Quarter Financial Results | 209 | GlobeNewswire (Europe) | Q1 reported revenue of $132.1 million increased 7%First quarter GAAP earnings of $0.04 per diluted share compared to the prior-year period loss of $0.04 per diluted shareNon-GAAP earnings* of $0.15... ► Artikel lesen | |
| 06.05. | Bioventus Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.05. | Bioventus Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.04. | Bioventus, Inc.: Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026 | 4 | GlobeNewswire (USA) | ||
| 06.03. | Craig-Hallum hebt Kursziel für Bioventus nach übertroffener Prognose an | 1 | Investing.com Deutsch | ||
| 06.03. | Craig-Hallum raises Bioventus stock price target on guidance beat | 2 | Investing.com | ||
| 05.03. | Bioventus outlines $600M-$610M 2026 sales target with accelerated investment in PNS, PRP, and ultrasonics | 1 | Seeking Alpha | ||
| 05.03. | Bioventus-Aktie springt nach übertroffenen Quartalserwartungen um 7,6 % | - | Investing.com Deutsch | ||
| 05.03. | Bioventus Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 05.03. | Bioventus Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 05.03. | Bioventus übertrifft Q4-Prognosen und gibt Ausblick für 2026 | 1 | Investing.com Deutsch | ||
| 05.03. | Bioventus Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TANGO THERAPEUTICS | 30,940 | +0,03 % | Tango Therapeutics stock soars on promising pancreatic cancer data | ||
| NURIX THERAPEUTICS | 15,640 | 0,00 % | Biotech-Partnerschaft: Roche greift zu: Dieser Milliarden-Deal lässt Anleger aufhorchen | © Foto: Vladimir Borovic - Adobe StockRoche steigt mit einem milliardenschweren Deal bei Nurix ein. Im Fokus steht ein vielversprechender Wirkstoff gegen Krebs, Autoimmun- und Nervenkrankheiten.Der... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,110 | 0,00 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| COGENT BIOSCIENCES | 31,160 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 82,94 | -0,08 % | RBC Capital raises Apogee Therapeutics stock price target to $97 | ||
| PRAXIS PRECISION MEDICINES | 253,12 | -0,05 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| ERASCA | 12,870 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,780 | 0,00 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| AMYLYX PHARMACEUTICALS | 13,010 | 0,00 % | H.C. Wainwright reiterates Amylyx stock rating on PBH trial insights | ||
| KINIKSA PHARMACEUTICALS | 49,040 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 22,500 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,000 | 0,00 % | Pictet closes $1.53bn Monte Rosa Co-Investments VI fund, exceeding target | ||
| DYNE THERAPEUTICS | 16,820 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1) | - Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 - WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage... ► Artikel lesen | |
| CG ONCOLOGY | 54,36 | -0,07 % | CG Oncology, Inc. - 8-K, Current Report | ||
| RELAY THERAPEUTICS | 13,660 | 0,00 % | Relay Therapeutics Shares Jump 18% |
Das Unternehmen BIOVENTUS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,010 (-0,11 %) liegt der Kurs bei 8,940 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOVENTUS INC finden Sie auf Wallstreet Online.